NO312464B1 - Utvalgte derivater av K-252a og anvendelse derav - Google Patents

Utvalgte derivater av K-252a og anvendelse derav Download PDF

Info

Publication number
NO312464B1
NO312464B1 NO19985622A NO985622A NO312464B1 NO 312464 B1 NO312464 B1 NO 312464B1 NO 19985622 A NO19985622 A NO 19985622A NO 985622 A NO985622 A NO 985622A NO 312464 B1 NO312464 B1 NO 312464B1
Authority
NO
Norway
Prior art keywords
compound
mmol
fab
synthesis
hydrogen
Prior art date
Application number
NO19985622A
Other languages
English (en)
Norwegian (no)
Other versions
NO985622D0 (no
NO985622L (no
Inventor
Robert L Hudkins
John P Mallamo
Masami Hamano
Rieko Tanaka
Chikara Murakata
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO985622D0 publication Critical patent/NO985622D0/no
Publication of NO985622L publication Critical patent/NO985622L/no
Publication of NO312464B1 publication Critical patent/NO312464B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO19985622A 1996-06-03 1998-12-02 Utvalgte derivater av K-252a og anvendelse derav NO312464B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65736696A 1996-06-03 1996-06-03
PCT/US1997/009448 WO1997046565A1 (fr) 1996-06-03 1997-06-02 DERIVES SELECTIONNES DU COMPOSE K-252a

Publications (3)

Publication Number Publication Date
NO985622D0 NO985622D0 (no) 1998-12-02
NO985622L NO985622L (no) 1999-02-02
NO312464B1 true NO312464B1 (no) 2002-05-13

Family

ID=24636859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985622A NO312464B1 (no) 1996-06-03 1998-12-02 Utvalgte derivater av K-252a og anvendelse derav

Country Status (18)

Country Link
US (1) US6306849B1 (fr)
EP (1) EP0918777B1 (fr)
JP (1) JP2000511902A (fr)
CN (1) CN1198827C (fr)
AT (1) ATE222912T1 (fr)
AU (1) AU716656B2 (fr)
BR (1) BR9711093A (fr)
CA (1) CA2256633C (fr)
DE (1) DE69715010T2 (fr)
DK (1) DK0918777T3 (fr)
ES (1) ES2183184T3 (fr)
HK (1) HK1018703A1 (fr)
NO (1) NO312464B1 (fr)
NZ (2) NZ333018A (fr)
PT (1) PT918777E (fr)
RU (1) RU2205184C2 (fr)
UA (1) UA67725C2 (fr)
WO (1) WO1997046565A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (fr) 1998-09-25 2007-05-09 Cephalon, Inc. Utilisation de pyrrolocarbazoles fusionnes pour la prevention/le traitement des cellules auditives ciliees et neurones cochleaires endommages
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
WO2004016167A1 (fr) * 2002-08-16 2004-02-26 The General Hospital Corporation Imagerie fonctionnelle non invasive de l'activation du systeme nerveux peripherique chez les humains et les animaux
CA2500901A1 (fr) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
MXPA05003502A (es) * 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
NZ540730A (en) * 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ATE491444T1 (de) * 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
DK2381964T3 (da) * 2008-12-22 2014-09-29 Creabilis S A Syntese af polymerkonjugater af indolocarbazolforbindelser

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Sf−2370物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質k−252の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ucn―01
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3835842A1 (de) 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
AU7035991A (en) 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質rk−1409、その製造法並びに抗腫瘍剤及び抗炎症剤
CA2123096A1 (fr) 1991-11-08 1993-05-13 Beat J. Knusel Compositions contenant des composes k-252 pour la potentialisation de l'activite neurotrophine
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Kk Verfahren zur Herstellung von Staurosporin-Derivaten
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ucn−01誘導体
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69331228D1 (en) * 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
ES2118414T3 (es) 1993-05-28 1998-09-16 Cephalon Inc Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
EP0703917A1 (fr) 1993-06-17 1996-04-03 Novartis AG Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
CN1198827C (zh) 2005-04-27
AU716656B2 (en) 2000-03-02
WO1997046565A1 (fr) 1997-12-11
NO985622D0 (no) 1998-12-02
CA2256633A1 (fr) 1997-12-11
CN1226893A (zh) 1999-08-25
ATE222912T1 (de) 2002-09-15
AU3225397A (en) 1998-01-05
RU2205184C2 (ru) 2003-05-27
NZ333018A (en) 2000-05-26
NO985622L (no) 1999-02-02
DE69715010T2 (de) 2003-04-03
PT918777E (pt) 2003-01-31
EP0918777A1 (fr) 1999-06-02
HK1018703A1 (en) 1999-12-30
JP2000511902A (ja) 2000-09-12
CA2256633C (fr) 2009-04-07
NZ504097A (en) 2005-06-24
DE69715010D1 (de) 2002-10-02
UA67725C2 (en) 2004-07-15
ES2183184T3 (es) 2003-03-16
EP0918777B1 (fr) 2002-08-28
BR9711093A (pt) 1999-08-17
US6306849B1 (en) 2001-10-23
DK0918777T3 (da) 2002-12-30

Similar Documents

Publication Publication Date Title
NO312464B1 (no) Utvalgte derivater av K-252a og anvendelse derav
JP5755739B2 (ja) β−アミロイド産生の減少のための化合物
JP6618120B2 (ja) TrkA阻害活性を有する複素環および炭素環誘導体
CN110156787B (zh) 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
EP3564239B9 (fr) Modulateur de récepteur d'hydrocarbure aryle
EP2949647B1 (fr) Composé d'aminopyrimidine phényle deutérié et composition pharmaceutique le contenant
CA3104757A1 (fr) Inhibiteur de necrose cellulaire, son procede de preparation et son utilisation
CZ297524B6 (cs) Sůl bis-indolylmaleimidu, farmaceutický prostředek s jejím obsahem a způsob její přípravy
WO2020188467A1 (fr) Composé tricyclique condensé utilisé en tant qu'inhibiteur de kinase
CN113993857A (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物
JP7118354B2 (ja) 三環式化合物の結晶形及びその使用
CN114292270A (zh) 一种btk抑制剂及其制备方法与应用
CN111704613A (zh) 咪唑类衍生物及其作为trpv4抑制剂的用途
TW202039457A (zh) 一類含氟取代的苯并噻吩類化合物及其藥物組合物及應用
US6875865B1 (en) Selected derivatives of K-252a
KR100485997B1 (ko) K-252의선택된유도체
EP4324834A1 (fr) Dérivé de pyridine bicyclique
US20240150370A1 (en) Bicyclic pyridine derivative
CN112703190B (zh) Hdac6选择性抑制剂的晶型及其应用
JP3749275B2 (ja) オキサゼピノピリドインドール誘導体及びその製造方法
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
JP2024055860A (ja) 二環性ピリジン誘導体を含有する医薬
KR20220131962A (ko) Ror 감마 조정제로서의 트리시클릭 술폰
CN113493452A (zh) 一种wnt通路抑制剂
KR100267595B1 (ko) 신규한 이소퀴놀린계 항암 활성 화합물

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees